Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07694440 · ClinicalTrials.gov registry record · Phase 2
A Phase 2 Study of MZE782 in Adults With PKU
A Phase 2 study, sponsored by Maze Therapeutics.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 38
- Enrollment target
NCT07694440: Recruiting Phase 2 study, sponsored by Maze Therapeutics.
NCT07694440 is a Phase 2 study that is actively recruiting participants, run by Maze Therapeutics. The registered enrollment target is 38 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (71% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT07694440, a Phase 2 study, is actively recruiting participants, sponsored by Maze Therapeutics.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 38 participants
- Enrollment target
Study Summary
The purpose of this study is to evaluate the safety, tolerability, and efficacy of MZE782 in adults with Phenylketonuria (PKU).
Interventions
- OTHER Placebo
- DRUG MZE782
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 38 participants |
| Start Date | 2026-06-23 |
| Est. Completion | 2028-02 |
| Phase | Phase 2 |
What NCT07694440 shows while recruiting
NCT07694440 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 38 participants, a relatively small participant target, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (71% lower).
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT07694440 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT07694440 about?
NCT07694440 is a clinical study titled "A Phase 2 Study of MZE782 in Adults With PKU". The purpose of this study is to evaluate the safety, tolerability, and efficacy of MZE782 in adults with Phenylketonuria (PKU).
What is the current status of trial NCT07694440?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 38 participants. The study started on 2026-06-23. Estimated completion is 2028-02.
What interventions are being tested in trial NCT07694440?
The interventions under investigation include: Placebo (OTHER), MZE782 (DRUG).
Who is sponsoring clinical trial NCT07694440?
This trial is sponsored by Maze Therapeutics, which has 3 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT07694440's enrollment target sits among peer trials
38 1467th of 2000 higher than 517 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01684904 · 38 participants · NA
Proton Therapy for Esophageal Cancer
- NCT03310879 · 38 participants · Phase 2
Study of the CDK4/6 Inhibitor Abemaciclib in Solid Tumors Harboring Genetic Alterations in Genes Encoding D-Type Cyclins or Amplification of CDK4 or CDK6
- NCT03896269 · 38 participants · Phase 1
CPX-351 in Treating Patients With Relapsed or Refractory High Risk Myelodysplastic Syndrome or Chronic Myelomonocytic Leukemia
- NCT04085315 · 38 participants · Phase 1
Alisertib in Combination With Osimertinib in Metastatic EGFR-mutant Lung Cancer
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI